Pyruvate attenuates the anti-neoplastic effect of carnosine independently from oxidative phosphorylation.
Here we analyzed whether the anti-neoplastic effect of carnosine, which inhibits glycolytic ATP production, can be antagonized by ATP production via oxidative phosphorylation fueled by pyruvate. Therefore, glioblastoma cells were cultivated in medium supplemented with glucose, galactose or pyruvate and in the presence or absence of carnosine. CPI-613 was employed to inhibit the entry of pyruvate into the tricarboxylic acid cycle and 2,4-dinitrophenol to inhibit oxidative phosphorylation. Energy metabolism and viability were assessed by cell based assays and histochemistry.ATP in cell lysates and dehydrogenase activity in living cells revealed a strong reduction of viability under the influence of carnosine when cells received glucose or galactose but not in the presence of pyruvate. CPI-613 and 2,4-dinitrophenol reduced viability of cells cultivated in pyruvate, but no effect was seen in the presence of glucose. No effect of carnosine on viability was observed in the presence of glucose and pyruvate even in the presence of 2,4-dinitrophenol or CPI-613.In conclusion, glioblastoma cells produce ATP from pyruvate via the tricarboxylic acid cycle and oxidative phosphorylation in the absence of a glycolytic substrate. In addition, pyruvate attenuates the anti-neoplastic effect of carnosine, even when ATP production via tricarboxylic acid cycle and oxidative phosphorylation is blocked. We also observed an inhibitory effect of carnosine on the tricarboxylic acid cycle and a stimulating effect of 2,4-dinitrophenol on glycolytic ATP production.
Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Leipzig AöR, 04103 Leipzig, Germany.
Henry
H
Oppermann
Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Leipzig AöR, 04103 Leipzig, Germany.
Lutz
L
Schnabel
Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Leipzig AöR, 04103 Leipzig, Germany.
Jürgen
J
Meixensberger
Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Leipzig AöR, 04103 Leipzig, Germany.
Frank
F
Gaunitz
D019297:2,4-Dinitrophenol / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002210:Caprylates / Q000494:pharmacology; D002336:Carnosine / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002952:Citric Acid Cycle; D004734:Energy Metabolism / Q000187:drug effects; D006801:Humans; D010085:Oxidative Phosphorylation; D019289:Pyruvic Acid / Q000494:pharmacology*; D013440:Sulfides / Q000494:pharmacology
D000970:Antineoplastic Agents; D002210:Caprylates; D013440:Sulfides; D019289:Pyruvic Acid; D002336:Carnosine; D000255:Adenosine Triphosphate; C568850:devimistat; D019297:2,4-Dinitrophenol
carnosine; glioblastoma; glucose; glycolysis; pyruvate